Multiple Sclerosis
Conference Coverage
Two MS meds tied to higher COVID rates
Conference Recap
Highlights in Relapsing-Remitting Multiple Sclerosis From AAN 2022
Updates in relapsing-remitting multiple sclerosis from 2022 AAN include abstracts on Mediterranean diet, ublituximab, BTK inhibitors,...
From the Journals
Childhood abuse may increase risk of MS in women
Women exposed to all three types of abuse – emotional, physical, and sexual – had the highest risk of MS, at 93%.
Conference Coverage
Neighborhood-level data sheds new light on racial and ethnic diversity in MS
Greater symptom burden in Black and Hispanic populations likely reflect socioeconomic factors.
Conference Coverage
Keto diet in MS tied to less disability, better quality of life
“The current study demonstrates the safety, tolerability, and potential clinical benefits of a ketogenic diet over 6 months in patients with...
Conference Recap
ACTRIMS 2022: Updates in Multiple Sclerosis Symptom Management
Dr Enrique Alvarez reports on ACTRIMS 2022 highlights including an analysis of nabiximols...
Conference Recap
Updates in DMTs and MS Economic Burden From ACTRIMS 2022
Dr Michael Wilson reviews updates from ACTRIMS 2022 on DMTs, autologous stem cell transplant, long-term tolebrutinib results as evident on MRI,...
Conference Coverage
Early MS biomarkers may improve prediction of long-term outcomes
Combining two biomarkers may shed more light on MS prognosis.
Conference Coverage
B-cell depletion overkill?
B-cell depletion following ocrelizumab or rituximab treatment often lasts longer than 6 months.
Conference Coverage
Home cognitive therapy looks feasible in MS
A randomized trial demonstrates how to deliver therapy at home.
Conference Coverage
DMTs tied to lower MS relapse during reproductive therapy
The likelihood of achieving pregnancy through assisted reproductive technologies while having MS appeared favorable.